{
    "clinical_study": {
        "@rank": "65414", 
        "arm_group": [
            {
                "arm_group_label": "Bevacizumab+TC", 
                "arm_group_type": "Experimental", 
                "description": "The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks."
            }, 
            {
                "arm_group_label": "TC", 
                "arm_group_type": "Active Comparator", 
                "description": "patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2\uff0c1 time/2 weeks for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To study the efficacy and safety of intraperitoneal injection bevacizumab combined with\n      intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of\n      ovarian cancer. To analyze the clinical significance of the concentration change of vascular\n      endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection\n      bevacizumab"
        }, 
        "brief_title": "Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy", 
        "condition": "Ovarian Cancer With Malignant Ascites", 
        "condition_browse": {
            "mesh_term": [
                "Ascites", 
                "Ovarian Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent obtained prior to initiation of any study-specific procedures\n             and treatment as confirmation of the patient's awareness and willingness to comply\n             with the study requirements.\n\n          -  Histologically confirmed and documented ovarian cancer with malignant ascites.\n\n          -  ECOG(Eastern Cooperative Oncology Group, ECOG) PS 0-2.\n\n          -  Life expectancy of >3 months.\n\n          -  No serious inadequate bone marrow function, liver and renal function or significant\n             cardiovascular disease.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to any of the study drugs or excipients.\n\n          -  Any current anti-cancer therapy.\n\n          -  No evidence of ascites.\n\n          -  Key organ dysfunction.\n\n          -  Significant cardiovascular disease (e.g. congestive heart failure (CHF), uncontrolled\n             cardiac arrhythmia, angina, heart valve disease, myocardial infarction and refractory\n             hypertension need to be long time controlled by medicine).\n\n          -  Non-healing wound, ulcer or bone fracture.\n\n          -  Uncontrolled psychiatric history."
            }, 
            "gender": "Female", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838538", 
            "org_study_id": "ML25396"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bevacizumab+TC", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Bevacizumab+TC", 
                    "TC"
                ], 
                "intervention_name": "TC:paclitaxel + carboplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bevacizumab", 
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 19, 2013", 
        "location": {
            "contact": {
                "email": "dunan05@yahoo.com.cn", 
                "last_name": "Nan Du, PhD", 
                "phone": "861068989123"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100048"
                }, 
                "name": "First Hospital Affiliated to the PLA General Hospital, Beijing,China"
            }, 
            "investigator": {
                "last_name": "Hui Zhao, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "dunan05@yahoo.com.cn", 
            "last_name": "Nan Du, PhD", 
            "phone": "861068989123"
        }, 
        "overall_contact_backup": {
            "email": "jihua.chen@roche.com", 
            "last_name": "Jihua Chen, MD", 
            "phone": "862128922576"
        }, 
        "overall_official": {
            "affiliation": "Chinese PLA General Hospital", 
            "last_name": "Zhao Hui, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "objective response rate", 
            "time_frame": "24month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838538"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "DuNan", 
            "investigator_title": "Chief Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}